Novavax, Inc. (NVAX)
After hours:
| Previous Close | 15.05 |
| Open | 14.40 |
| Bid | 14.38 x 2400 |
| Ask | 14.41 x 2400 |
| Day's Range | 13.50 - 14.89 |
| 52 Week Range | 3.53 - 23.86 |
| Volume | |
| Avg. Volume | 14,814,230 |
| Market Cap | 2.121B |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.05 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
PR NewswireNovavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from the U.S. FDA, European Medicines Agency (EMA) and the World Health Organization (WHO) to target the JN.1 lineage this fall.1-3
Investor's Business DailyThe FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Novavax stock seesawed on June 6 after the FDA assigned an April review date for its Covid vaccine. Is NVAX stock a buy right now?
ZacksModerna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
